Increasing soluble AXL (sAXL) levels in blood has been reported by Flem–Karlsen and colleagues as being associated with melanoma disease progression and correlated with shorter two-year survival in stage IV patients treated with ipilimumab [47]. The gene discussed is AXL; the disease is melanoma.